Citations

Clear

3501 citation(s) found for "Xu, Timothy".

Three Hours of Intermittent Hypoxia in Young Healthy Humans Induces Electrocardiographic Changes
Newhouse, Lauren P., Limberg, Jacqueline K. , Baker, Sarah E. , Joyner, Michael J. , Curry, Timothy B.

Mayo Clinic

The FASEB Journal | November 26, 2023 | Volume: 30 | Issue: S1 | Pages: No page available

10.1096/fasebj.30.1_supplement.1007.5 Get It

Background Individuals with sleep apnea experience repeated intermittent hypoxic exposures during sleep. Previous work in sleep apnea showed patients have an increased heart rate (HR), corrected QT interval (QTc), QTc dispersion and P‐wave maximum duration and dispersion (max‐min P‐wave duration). Such changes have been linked to increased risk of cardiovascular disease and sudden cardiac death. Unfortunately, the mechanisms contributing to these changes are not completely understood. Given that individuals with sleep apnea experience repeated intermittent hypoxic exposures during sleep, we tested the hypothesis that exposure to intermittent hypoxia (IH) in young healthy adults would result in similar ECG changes to those seen in patients with sleep apnea. Methods To test this hypothesis, we completed ECG analysis of 7 healthy humans (6M/1F, Age=29±5 years, BMI=24±4kg/m 2 ) without sleep apnea before and after 3‐hours of exposure to IH. Subjects were exposed to hypoxic gas (0.05 FiO2) for 25‐seconds separated by 2‐minutes of room air breathing. This resulted in 25 hypoxic events per hour in which oxygen saturation was significantly reduced (Normoxia: 97%, Hypoxia: 89%, p<0.01). ECG analysis was completed in Lab Chart 7 software and consisted of measurement of intervals (RR, PR, QT), durations (P, QRS), and amplitudes (P, Q, R, S, T) during 10 minutes of normoxic quiet rest before and after IH exposure. QTc was calculated using Bazett's formula (QT duration/√HR). Dispersion of QTc and P waves were calculated as max duration ‐min duration. Results HR was significantly increased following IH (60±8 vs. 66±8 beats/min, baseline vs. post‐IH, respectively, p<0.05). There was no significant change in P‐wave maximum duration or dispersion following IH. QT interval was significantly decreased and QTc was significantly increased following IH (QT interval: 377±13 vs. 368±8ms, QTc: 377±22 vs 384±22ms, baseline vs. post‐IH, p<0.05 for both). QTc dispersion was not significantly different from baseline following IH. Conclusions We found that 3 hours of experimentally‐induced IH in young healthy individuals resulted in increased HR, decreased QT interval, and increased QTc. These data suggest that IH exposure experienced by patients with sleep apnea may contribute to ECG changes commonly observed in this population and subsequent increases in cardiovascular morbidity and mortality. Support or Funding Information Funding : DK90541 (MJJ), HL120570 (JKL)
3 Hours of Intermittent Hypoxia Increases Circulating Glucose Levels in Healthy Adults
Newhouse, Lauren P., Limberg, Jacqueline K. , Joyner, Michael J. , Curry, Timothy B.

Mayo Clinic

The FASEB Journal | November 26, 2023 | Volume: 30 | Issue: S1 | Pages: No page available

10.1096/fasebj.30.1_supplement.1000.1 Get It

Background We have previously shown that the carotid body chemoreceptors play an important role in glucoregulation. When the carotid bodies are experimentally desensitized in humans, counterregulatory responses to hypoglycemia are attenuated. Whether carotid body activation conversely increases circulating glucose levels was previously unexamined. We hypothesize plasma glucose levels would be increased in young healthy adults after carotid body activation via acute intermittent hypoxia. Methods Seven (6M/1F, 21–34 years) healthy, non‐obese, non‐diabetic, subjects without sleep apnea completed 2 visits randomized to 3‐hours of intermittent hypoxia or continuous normoxia. Oxygen saturation and ventilation (turbine ventilation flow transducer) were measured continuously. Plasma glucose levels and carotid body chemosensitivity (hypoxic ventilatory response, HVR) were measured before and after the 3‐hour protocol. Intermittent hypoxia consisted of 25‐s exposures to hypoxic gas (0.05 FiO 2 ) separated by 2‐min of room air breathing, resulting in 25‐events per hour in which oxygen saturation was significantly reduced (Normoxia: 97%, Hypoxia: 89%, p<0.01). Results No changes in plasma glucose (93 vs 93 mg/dL, p=0.92) or HVR (−0.35 vs. −0.39 L/min/%SpO 2, p=0.56) were observed after 3‐hours of continuous normoxia. In contrast, circulating glucose levels and chemosensitivity increased after intermittent hypoxia when compared to baseline (92 vs 97 mg/dL, p<0.01) and (−0.39 vs −0.60 L/min/%SpO 2 , p=0.04), respectively. Additionally, the rise in glucose was significantly correlated with the rise in carotid body chemosensitivity (R=0.38, p=0.05). Conclusion Circulating glucose levels increased after 3‐hours of intermittent hypoxia. The significant relationship between HVR and circulating glucose suggests that the carotid bodies may play a role in altered glucose handling. These findings may have important implications for the high prevalence of diabetes in patients with sleep apnea. Support or Funding Information DK90541, HL120570
Effect of pulmonary flow heterogeneity and impaired diffusing capacity on oxygen uptake
Roy, Tuhin K. , Secomb, Timothy W.

Mayo Clinic

The FASEB Journal | November 26, 2023 | Volume: 30 | Issue: S1 | Pages: No page available

10.1096/fasebj.30.1_supplement.946.4 Get It

Severe impairment of oxygenation in critically ill patients is a major cause of morbidity and mortality, and can occur even with normal alveolar ventilation and cardiac output under conditions of decreased diffusing capacity or increased flow heterogeneity. A theoretical model of pulmonary oxygen uptake under resting conditions is used to simulate decreased diffusing capacity (DL) as well as increased heterogeneity (characterized by an increase in the coefficient of variation [CV] of pulmonary capillary blood flow), with the assumed normal value of CV based on observations of microvascular networks. Under resting conditions with nominal values of DL and CV, the model predicts an oxygen saturation (SO 2 ) of 97% (PO 2 = 94 mmHg). Simulating a 10‐fold reduction in DL leads to an SO 2 of 85% (PO 2 = 51 mmHg), whereas doubling the CV from its normal value leads to an SO 2 of 95% (PO 2 = 78 mmHg); both of these predictions suggest a high degree of reserve in the healthy resting lung. However, simulating these conditions simultaneously leads to a large reduction in SO 2 to 71% (PO 2 = 37 mmHg), exhausting the reserve capacity of the lung and demonstrating the detrimental synergistic effect of heterogeneity in the context of an attenuated diffusing capacity. These results imply that a combination of increased heterogeneity and decreased diffusing capacity can explain the severe impairment in pulmonary oxygen uptake and decreased saturations seen in critical illness. Support or Funding Information Supported by NIH grant HL070657.
BrAIST-Calc: Prediction of Individualized Benefit From Bracing for Adolescent Idiopathic Scoliosis
Dolan, Lori A. , Weinstein, Stuart L. , Dobbs, Matthew B. , Flynn, John M. , Halsey, Matthew F. , Hresko, M. Timothy , Krengel, Walter F. , Mehlman, Charles T. , Milbrandt, Todd A. , Price, Nigel, Schmitz, Michael L. , Song, Kit M., Talwalkar, Vishwas, Weinstein, Stuart L , Green, Daniel W , Newton, Peter O. , Sanders, James O , Schwend, Richard M. , Shah, Suken A.

Mayo Clinic

Spine | November 23, 2023 | Volume: 49 | Issue: 3 | Pages: 147-156

10.1097/brs.0000000000004879 | PMID 37994691 Get It

Study Design. Prospective multicenter study data were used for model derivation and externally validated using retrospective cohort data. Objective. Derive and validate a prognostic model of benefit from bracing for adolescent idiopathic scoliosis (AIS). Summary of Background Data. The Bracing in Adolescent Idiopathic Scoliosis Trial (BrAIST) demonstrated the superiority of bracing over observation to prevent curve progression to the surgical threshold; 42% of untreated subjects had a good outcome, and 28% progressed to the surgical threshold despite bracing, likely due to poor adherence. To avoid over-treatment and to promote patient goal setting and adherence, bracing decisions (who and how much) should be based on physician and patient discussions informed by individual-level data from high-quality predictive models. Materials and Methods. Logistic regression was used to predict curve progression to <45° at skeletal maturity (good prognosis) in 269 BrAIST subjects who were observed or braced. Predictors included age, sex, body mass index, Risser stage, Cobb angle, curve pattern, and treatment characteristics (hours of brace wear and in-brace correction). Internal and external validity were evaluated using jackknifed samples of the BrAIST data set and an independent cohort (n=299) through estimates of discrimination and calibration. Results. The final model included age, sex, body mass index, Risser stage, Cobb angle, and hours of brace wear per day. The model demonstrated strong discrimination ( c -statistics 0.83–0.87) and calibration in all data sets. Classifying patients as low risk (high probability of a good prognosis) at the probability cut point of 70% resulted in a specificity of 92% and a positive predictive value of 89%. Conclusion. This externally validated model can be used by clinicians and families to make informed, individualized decisions about when and how much to brace to avoid progression to surgery. If widely adopted, this model could decrease overbracing of AIS, improve adherence, and, most importantly, decrease the likelihood of spinal fusion in this population.
Cardiometabolic outcomes in Kronos Early Estrogen Prevention Study continuation: 14-year follow-up of a hormone therapy trial
Kantarci, Kejal , Tosakulwong, Nirubol , Lesnick, Timothy G. , Kendall‐Thomas, June, Kapoor, Ekta , Fields, Julie A. , James, Taryn T. , Løbo, Rogerio A. , Pal, Lubna , Hammers, Dustin B. , Cedars, Marcelle I. , Miller, Virginia M. , Harman, S. Mitchell , Gleason, Carey E. , Kendall-Thomas, June, Kantarci, Kejal , Kara, Firat , Manson, JoAnn E. , Hammers, Dustin B , Malek‐Ahmadi, Michael , Naftolin, Frederick , Santoro, Nanette F. , Dowling, N. Maritza

Mayo Clinic

Menopause | November 21, 2023 | Volume: 31 | Issue: 1 | Pages: 10-17

10.1097/gme.0000000000002278 | PMID 37989141 Get It

Abstract Objective This study aimed to determine long-term cardiometabolic effects of hormone therapies initiated within 3 years of onset of menopause after a 14-year follow-up study of participants of the Kronos Early Estrogen Prevention Study (KEEPS). Methods KEEPS was a multisite clinical trial that recruited recently menopausal women with good cardiovascular health for randomization to oral conjugated equine estrogens (Premarin, 0.45 mg/d) or transdermal 17β-estradiol (Climara, 50 μg/d) both with micronized progesterone (Prometrium, 200 mg/d) for 12 d/mo, or placebo pills and patch for 4 years. KEEPS continuation recontacted KEEPS participants 14 years after randomization and 10 years after the completion of the 4-year clinical trial to attend in-person clinic visits. Results Participants of KEEPS continuation (n = 299 of the 727 KEEPS participants; 41%) had an average age of 67 years (range, 58-73 y). Measurements of systolic and diastolic blood pressures, waist-to-hip ratio, fasting levels of glucose, insulin, lipid profiles, and homeostasis model assessment of insulin resistance were not different among the treatment groups at either KEEPS baseline or at KEEPS continuation visits, or for change between these two visits. The frequency of self-reported diabetes ( P = 0.007) and use of diabetes medications was higher in the placebo than the oral conjugated equine estrogens ( P = 0.045) or transdermal 17β-estradiol ( P = 0.02) groups, but these differences were not supported by the laboratory measurements of glycemia or insulin resistance. Conclusions There was no evidence of cardiovascular and/or metabolic benefits or adverse effects associated with 4 years use of oral or transdermal forms of hormone therapy by recently menopausal women with good cardiovascular health after 10 years.
Sudden Cardiac Death in National Collegiate Athletic Association Athletes: A 20-Year Study
Petek, Bradley J. , Churchill, Timothy W. , Moulson, Nathaniel , Kliethermes‌, Stephanie , Baggish, Aaron L. , Drezner, Jonathan A. , Patel, Manesh R. , Ackerman, Michael J. , Kucera, Kristen L. , Siebert, David M., Salerno, Lauren, Suchsland, Monica Zigman , Asif, Irfan M. , Maleszewski, Joseph J. , Kliethermes, Stephanie A , Zigman Suchsland, Monica , Harmon, Kimberly G , Drezner, Jonathan A , Churchill, Timothy W , Baggish, Aaron L , Harmon, Kimberly G.

Mayo Clinic

Circulation | November 13, 2023 | Volume: 149 | Issue: 2 | Pages: 80-90

10.1161/circulationaha.123.065908 | PMID 37955565 Get It

BACKGROUND: Understanding the incidence, causes, and trends of sudden cardiac death (SCD) among young competitive athletes is critical to inform preventive policies. METHODS: This study included National Collegiate Athletic Association athlete deaths during a 20-year time frame (July 1, 2002, through June 30, 2022). Athlete deaths were identified through 4 separate independent databases and search strategies (National Collegiate Athletic Association resolutions list, Parent Heart Watch database and media reports, National Center for Catastrophic Sports Injury Research database, and insurance claims). Autopsy reports and medical history were reviewed by an expert panel to adjudicate causes of SCD. RESULTS: A total of 143 SCD cases in National Collegiate Athletic Association athletes were identified from 1102 total deaths. The National Collegiate Athletic Association resolutions list identified 117 of 143 (82%), the Parent Heart Watch database or media reports identified 89 of 143 (62%), the National Center for Catastrophic Sports Injury Research database identified 63 of 143 (44%), and insurance claims identified 27 of 143 (19%) SCD cases. The overall incidence of SCD was 1:63 682 athlete-years (95% CI, 1:54 065–1:75 010). Incidence was higher in male athletes than in female athletes (1:43 348 [95% CI, 1:36 228–1:51 867] versus 1:164 504 [95% CI, 1:110 552–1:244 787] athlete-years, respectively) and Black athletes compared with White athletes (1:26 704 [1:20 417–1:34 925] versus 1:74 581 [1:60 247–1:92 326] athlete-years, respectively). The highest incidence of SCD was among Division I male basketball players (1:8188 [White, 1:5848; Black, 1:7696 athlete-years]). The incidence rate for SCD decreased over the study period (5-year incidence rate ratio, 0.71 [95% CI, 0.61–0.82]), whereas the rate of noncardiovascular deaths remained stable (5-year incidence rate ratio, 0.98 [95% CI, 0.94–1.04]). Autopsy-negative sudden unexplained death (19.5%) was the most common postmortem examination finding, followed by idiopathic left ventricular hypertrophy or possible cardiomyopathy (16.9%) and hypertrophic cardiomyopathy (12.7%), in cases with enough information for adjudication (118 of 143). Eight cases of death were attributable to myocarditis over the study period (1 case from January 1, 2020, through June 30, 2022), with none attributed to COVID-19 infection. SCD events were exertional in 50% of cases. Exertional SCD was more common among those with coronary artery anomalies (100%) and arrhythmogenic cardiomyopathy (83%). CONCLUSIONS: The incidence of SCD in college athletes has decreased. Male sex, Black race, and basketball are associated with a higher incidence of SCD.
CTNI-73. ALLIANCE A071601: PHASE II TRIAL OF BRAF/MEK INHIBITION IN NEWLY DIAGNOSED PAPILLARY CRANIOPHARYNGIOMAS
Twohy, Erin , Geyer, Susan, Gerstner, Elizabeth R. , Kabat, Brian, Thierauf, Julia , Ruff, Michael W. , Reardon, David A. , Cohen, Adam L. , Fuente, Macarena de la, Lesser, Glenn J. , Campian, Jian , Agarwalla, Pankaj K., Kumthekar, Priya , Mann, Bhupinder, Vora, Shivangi, Knopp, Michael, Iafrate, A. John , Brown, Paul D. , Barker, Frederick G., Brastianos, Priscilla K. , Kaufmann, Timothy J. , Tabrizi, Shervin , Bota, Daniela A. , Knopp, Michael V. , Curry, William T. , Cahill, Daniel P. , Shih, Helen A. , Santagata, Sandro , Galanis, Evanthia

Mayo Clinic

Neuro-Oncology | November 11, 2023 | Volume: 25 | Issue: Supplement_5 | Pages: v94-v94

10.1093/neuonc/noad179.0355 Get It

Abstract BACKGROUND Craniopharyngiomas, primary brain tumors of the pituitary-hypothalamic axis, can cause significant clinical sequelae. Treatment using surgery, radiation, or both often entails significant morbidity. In prior work, we demonstrated that ninety-five percent of papillary craniopharyngiomas (PCP) harbor BRAF V600E mutations (Brastianos et al. Nature Genetics 2014). In this multicenter National Cancer Institute cooperative group trial (Alliance A071601), we evaluated the safety and efficacy of BRAF/MEK inhibition in patients with PCP without prior irradiation. METHODS Eligible patients, with measurable disease and whose PCP screened positively for BRAF mutations, without prior radiation, received the BRAF/MEK inhibitor combination vemurafenib/cobimetinib in 28-day cycles. The primary endpoint of objective response rate at 4 months based on centrally determined volumetric data was evaluated in 16 patients on this single arm phase 2 trial. RESULTS Based on volumetric response criteria by central radiology review, 15 of 16 patients (94%; 95% CI: 70% to 100%) had a durable objective partial response to therapy. Thus, this study met primary endpoint for overall response rate. The median tumor reduction was 91% (range of 68% to 99%). Median follow-up was 22 months (95% CI: 19 to 30 months) and median number of treatment cycles was 8. Median progression-free survival and duration of response were not yet reached. Three patients progressed during follow-up after therapy was discontinued; none have died. The sole non-responder stopped treatment after eight days due to toxicity. Grade 3 toxicities at least possibly related to treatment occurred in 12 patients (rash in 6 patients). Grade 4 toxicities were observed in two patients: hyperglycemia (n=1) and increased creatine phosphokinase (n=1). Three patients discontinued treatment for adverse events. CONCLUSIONS Our study indicates that BRAF/MEK inhibitors are a safe and effective treatment for PCP without prior irradiation. Support: U10CA180821, U10CA180882; U24CA196171, U10CA180868 (NRG); Genentech; . ClinicalTrials.gov Identifier: NCT03224767.
The role of serum lipoprotein(a) levels in bioprosthetic aortic valve degeneration
Fariña, Juliana, Roarke, M., Barry, Timothy, Sweeney, John P., Fortuin, David, Lester, Steven J., Oh, Jae K. , Marcotte, F, Pereyra, Milagros , Pereyra, Milagros , Farina, J, Chao, Chieh‐Ju , Said, E, Alsidawi, Said , Sell‐Dottin, Kristen , Ayoub, C, Arsanjani, Reza

Mayo Clinic

European Heart Journal | November 11, 2023 | Volume: 44 | Issue: Supplement_2 | Pages: No page available

10.1093/eurheartj/ehad655.1616 Get It

Abstract Introduction Lipoprotein(a) [Lp(a)] is associated with an increased incidence of aortic stenosis. Bioprosthetic aortic valve degeneration and native aortic stenosis share similar pathological mechanisms. Evidence regarding the role of serum Lp(a) concentrations in bioprosthetic aortic valve degeneration is lacking. Purpose To evaluate the association between serum Lp(a) concentrations and bioprosthetic aortic valve degeneration. Methods In this retrospective multicenter study, consecutive patients who underwent a bioprosthetic aortic valve replacement between Jan-2010 and Dec-2020 and had a preoperatory serum Lp(a) measurement were included. A baseline transthoracic echocardiography (TTE) was performed following the aortic valve replacement and a follow-up TTE was performed at least 24 months after the baseline study to determine the presence of bioprosthetic valve degeneration. Significant degeneration was defined as: (a) an increase &gt;10 mmHg in mean bioprosthetic aortic valve gradient from baseline status + a decrease in effective orifice area + a decrease in Doppler velocity index + exclusion of clinically thrombotic leaflet thickening, OR (b) new moderate or severe prosthetic aortic regurgitation (if the main component was periprosthetic, then it was not considered). Lp(a) concentrations were compared between patients with and without degeneration and regression analysis was conducted to investigate the association between bioprosthetic valve degeneration and Lp(a) levels. Results In total, 211 cases were included (mean age 74.1 ±9.4 years, 72.0% males, 29.9% transcatheter aortic valve replacements) (Figure 1). Median time between baseline and follow-up TTE was 5.0 (IQR 3.7) years. Bioprostheses degeneration was observed in 33 (15.6%) patients at follow-up. Median serum levels of Lp(a) were significantly higher in the patients affected by degeneration versus non-affected cases (50.0 vs 15.7 mg/dl, p=0.003). In the regression analysis, high Lp(a) levels (≥30 mg/dl) were associated with degeneration both in a univariate analysis (OR 4.8, 95%CI 2.2-10.9, p&lt;0.001) and multivariate analysis adjusted by other risk factors for bioprostheses degeneration (age, sex, hypertension, smoking, patient prosthesis mismatch, creatinine levels, and body surface area) (OR 5.2, 95%CI 2.1-12.8, p&lt;0.001). Conclusion Serum Lp(a) concentrations seem to be a risk factor for bioprosthetic aortic valve degeneration (Figure 2). There is an increasing need to accurately predict bioprosthetic aortic valve degeneration and to develop novel methods and treatments to increase their durability. Prospective studies are needed to confirm these findings and to investigate whether lowering Lp(a) could slow bioprostheses degradation.Population characteristicsLp(a) and bioprostheses degeneration
Case series: cardiac sarcoma
Killian, Michael , Barry, Timothy , Alsidawi, Said , Larsen, Carolyn , Alsidawi, Said

Mayo Clinic

European Heart Journal - Case Reports | November 9, 2023 | Volume: 7 | Issue: 12 | Pages: No page available

10.1093/ehjcr/ytad546 | PMID 38046649 Get It

Abstract Background Cardiac masses encompass a wide differential including primary and secondary malignancies and can present with a variety of symptoms, many of which are non-specific. Early identification and classification are important, particularly for cardiac malignancies such as sarcomas as these are aggressive tumours with exceptionally poor prognoses when metastases are present at diagnosis. Case summary We report two cases of patients who presented with dyspnoea and were diagnosed with cardiac sarcomas; the former a primary sarcoma (undifferentiated pleomorphic subtype) and the latter a secondary sarcoma (round cell myxoid liposarcoma) that serve as comparisons for presentation and management of different types of this disease. Computed Tomography (CT) and echocardiography imaging findings are demonstrated showing the typical location and morphology of each subtype. Discussion Cardiac sarcomas are the most common primary cardiac malignancy, of which undifferentiated pleomorphic sarcoma is a common subtype. Undifferentiated pleomorphic sarcomas are aggressive, have a tendency to arise in the left atrium, and can appear similar to benign cardiac masses. Round cell myxoid liposarcomas by contrast are rare causes of secondary cardiac malignancies, metastasizing to the heart from soft tissues. Both diagnoses carry poor prognoses and although rare, are important to recognize as timely intervention with surgery, radiotherapy, and consideration of chemotherapy is key to maximizing survival.
Vascular risk, gait, behavioral, and plasma indicators of VCID
Raghavan, Sheelakumari , Przybelski, Scott A. , Lesnick, Timothy G. , Fought, Angela J. , Gebre, Robel K , Windham, B. Gwen , Vassilaki, Maria , Jack, Clifford R. , Petersen, Ronald C. , Graff‐Radford, Jonathan , Vemuri, Prashanthi , Jack, Clifford R , Vemuri, Prashanthi , Reid, Robert I. , Algeciras‐Schimnich, Alicia , Machulda, Mary M. , Knopman, David S.

Mayo Clinic

Alzheimer's & Dementia | November 7, 2023 | Volume: 20 | Issue: 2 | Pages: 1201-1213

10.1002/alz.13540 | PMID 37932910 Get It

AbstractINTRODUCTIONCost‐effective screening tools for vascular contributions to cognitive impairment and dementia (VCID) has significant implications. We evaluated non‐imaging indicators of VCID using magnetic resonance imaging (MRI)‐measured white matter (WM) damage and hypothesized that these indicators differ based on age.METHODSIn 745 participants from the Mayo Clinic Study of Aging (≥50 years of age) with serial WM assessments from diffusion MRI and fluid‐attenuated inversion recovery (FLAIR)‐MRI, we examined associations between baseline non‐imaging indicators (demographics, vascular risk factors [VRFs], gait, behavioral, plasma glial fibrillary acidic protein [GFAP], and plasma neurofilament light chain [NfL]) and WM damage across three age tertiles.RESULTSVRFs and gait were associated with diffusion changes even in low age strata. All measures (VRFs, gait, behavioral, plasma GFAP, plasma NfL) were associated with white matter hyperintensities (WMHs) but mainly in intermediate and high age strata.DISCUSSIONNon‐imaging indicators of VCID were related to WM damage and may aid in screening participants and assessing outcomes for VCID.Highlights Non‐imaging indicators of VCID can aid in prediction of MRI‐measured WM damage but their importance differed by age. Vascular risk and gait measures were associated with early VCID changes measured using diffusion MRI. Plasma markers explained variability in WMH across age strata. Most non‐imaging measures explained variability in WMH and vascular WM scores in intermediate and older age groups. The framework developed here can be used to evaluate new non‐imaging VCID indicators proposed in the future.